



**PRE-CONFERENCE EDUCATIONAL SESSIONS**

Date & Time	Room	Session
Thursday, Aug 23 8:30 AM – 12:30 PM	South Hall C	Intermediate Pharmacoepidemiology: Approaches to Unmeasured Confounding <ul style="list-style-type: none"> <li>▪ Use of Study Design to Control Unmeasured Confounding, <b>Jennifer Lund</b></li> <li>▪ Analytic Approaches to Unmeasured Confounding, <b>Til Stürmer, Jennifer Lund, Michele Jonsson Funk</b></li> <li>▪ Interactive Case Study, <b>Michele Jonsson Funk</b></li> </ul>

**ACADEMIC SHOWCASE**

Come meet us at our table at the Academic Showcase. Thursday, Aug 23, 6:00 – 7:30 PM, Zoom/Panorama

**FRIDAY, AUGUST 24. ORAL PRESENTATIONS & SYMPOSIA**

Time	Session & Room	Presentation
2:30 PM	OR05 Methods: It's About Time – Congress Hall	Estimating Cumulative Risk in the Presence of Competing Events and Dependent Censoring in Pharmacoepidemiology Studies <b>Sara Levintow, Leah McGrath and M Alan Brookhart</b>
2:30 PM	OR11 Drugs in Pregnancy - South Hall 2A	Comparative Safety of Ondansetron Use During Pregnancy <b>Elizabeth A Suarez, Michele Jonsson Funk</b>
5:15 PM	OR02 Methods for Data Far and Wide – Panorama Hall	Performance of Fixed and All-Available Look-Back Approaches in Claims Database Studies: a Plasmode Simulation <b>Mitchell M Conover, Til Stürmer, Charles Poole, Robert J Glynn, Ross J Simpson, Jr, and Michele Jonsson Funk</b>
5:15 PM	OR18 Heart & Limbs – South Hall 2B	Sodium-Glucose Cotransporter-2 Inhibitor Use and Lower-Extremity Amputation Risk Among Commercially-Insured U.S. Patients, 2013-2015 <b>Jeff Y Yang, John B Buse, Emily W Gower, Virginia Pate, Tiansheng Wang and Til Stürmer</b>

**FRIDAY, AUGUST 24. POSTER SESSION A, CONGRESS FOYER 2 & 3, 8AM – 6PM**

Session	Poster
PO01-04 CER	Presentation 110 / BB Comparison of Propensity Score (PS) Weighting and Trimming Strategies to Reduce Variance and Bias of Treatment Effect Estimates: a Simulation Study <b>Til Stürmer, Kenneth J Rothman, Alan R Ellis, Richard Wyss, Mitchell Conover, Mark Lunt and Robert J Glynn</b>
PO01-08 Burden of disease	Presentation 144 / 26 Self-Reported Comorbidity, Functional Dependence and Healthcare Resource Utilization of Chronic Hepatitis C Virus Infection Patients <b>Phyo Htoo, Ning (Jackie) Zhang and Jinghua He</b>
PO01-10 Burden of disease	Presentation 177 / 59 Chronic Kidney Disease (CKD) in US Adults With Type 2 Diabetes (T2D) and/or Cardiovascular Diseases (CVD): a National Estimate of Prevalence by KDIGO 2012 Classification <b>Tongtong Wang, Yuzhi Xi, Robert Lubwama and Carol Koro</b>
PO01-10 Burden of disease	Presentation 173 / 55 Predictors of Outpatient Cardiac Rehabilitation Referral Among Hospitalized Heart Failure Patients: the Atherosclerosis Risk in Communities (ARIC) Study <b>Sydney T Thai, Wayne D Rosamond, Anthony J Viera, Patricia P Chang, Salim S Virani, M Alan Brookhart, Montika Bush, Laura R Loehr, June Stevens and Anna Kucharska-Newton</b>
PO01-11 Data Linkage	Presentation 185 / 67 Linking Electronic Health Data in Pharmacoepidemiology: Guidance for Assessing Appropriateness and Feasibility <b>Donna R Rivera, Mugdha N Gokhale, Matthew W Reynolds, Elizabeth B Andrews, Danielle Chun, Kevin Haynes, Michele Jonsson Funk, Kristine E Lynch, Jennifer L Lund, Helen Strongman and Sudha R Raman</b>
PO01-15 Drug Utilization	Presentation 221 / 103 Predictors of Tyrosine Kinase Inhibitor Treatment for Chronic Myeloid Leukemia <b>Ashley L Cole, William A Wood, Benyam Muluneh, Jennifer L Lund, Jennifer Elston Lafata and Stacie B Dusetzina</b>

PO01-16 Drug Utilization	Presentation 234 / 116 When Prescriptions Fall Short: Using CPT Codes to Augment Warfarin Prescriptions in Claims <b>Michael A Webster-Clark, Jennifer Lund and Virginia Pate</b>
PO01-17 Informatics	Presentation 238 / 120 An Application of Machine Learning for the Refinement of an EHR-Derived Cohort <b>Sarah R Hoffman, Emily R Pfaff and Wanda K Nicholson</b>
PO01-19 Methods-Validation	Presentation 264 / 146 A Flexible Approach to Evaluating the Validity of Commonly Used Claims-Based Cancer Algorithms <b>Monica D'Arcy, Til Stürmer and Jennifer L Lund</b>
PO01-19 Methods-Validation	Presentation 276 / 158 Predicting Out-Of-Hospital Death Using Insurance Claims Data <b>Jessica C Young, Debra E Irwin, Ashley L Cole, Virginia Pate and Michele Jonsson Funk</b>
PO01-19 Methods-Validation	Presentation 280 / 162 Determining Infant Age From Administrative Claims Data Without Birth Date: a Validation Study <b>Julia B Ward, Casey Pierce, John Lim, Brian R Matlaga and Lydia Feinstein</b>
PO01-25 Drug Utilization	Presentation 343 / 225 Changes in Diabetes Medication Adherence in Older Cancer Patients versus Matched Cancer-Free Cohorts: a Difference-In-Difference Analysis <b>Jennifer L Lund, Ke Meng, Benjamin Y Urick, Krutika Amin, Stephanie B Wheeler, Katherine E Reeder-Hayes and Justin G Trogdon</b>
PO01-26 Methods to avoid bias and confounding	Presentation 360 / 242 Multiple Imputation of Clinical Variables in FFS Medicare Population <b>Tiansheng Wang, Emily W Gower, Jennifer L Lund, Michele Jonsson Funk, Virginia Pate, John B Buse and Til Stürmer</b>

#### SATURDAY, AUGUST 25. ORAL PRESENTATIONS & SYMPOSIA

Time	Session & Room	Presentation
8:00 AM	ORO3 Diversity in Design: A Mismatch of Methods – Congress Hall	Variation in Risk Estimates From Different Cohort Selection Strategies When Using Recurrent Index Events <b>Henry T Zhang, Mitchell M Conover and Til Stürmer</b>
8:00 AM	OR10 Advances in Vaccine Safety Monitoring – Panorama Hall	Effectiveness of Prenatal Tdap in the Prevention of Infant Pertussis in the US <b>Sylvia Becker-Dreps, Anne M Butler, Leah J McGrath, Kim A Boggess, David J Weber, Dongmei Li, Michael G Hudgens and J. Bradley Layton</b>
8:15 AM	ORO3 Diversity in Design: A Mismatch of Methods – Congress Hall	Implementation of the Prevalent New User Study Design in the Us Medicare Population: Benefit versus Harm <b>Elizabeth Garry, John B Buse, Mugdha Gokhale, Jennifer L. Lund, Virginia Pate and Til Stürmer</b>
8:30 AM	OR33 Painful Policy – South Hall 3A	Identifying Off-Label Pharmaceutical Company Promotion of Opioids for Cancer Pain Management <b>Shelley A. Jazowski, Stephen Patrick and Stacie B Dusetzina</b>
9:00 AM	ORO3 Diversity in Design: A Mismatch of Methods – Congress Hall	Strategies for Selecting Start of Follow-Up in Longitudinal Studies With Multiple Eligible Index Opportunities <b>Mitchell M Conover, Henry T Zhang, Til Stürmer, Robert J Glynn, Charles Poole and Michele Jonsson Funk</b>
9:15 AM	ORO3 Diversity in Design: A Mismatch of Methods – Congress Hall	Implementation of the Trend-In-Trend Study Design in a Setting With Cross-Over of Preferred Treatment Choice: An Example of Second-Line Antidiabetics <b>Phyo T Htoo, John Buse, Virginia Pate and Til Stürmer</b>
1:15 PM	Session OR29 Geriatric Management and Measurements – South Hall 2A	Improving Claims-Based Frailty Prediction in the Medicare Population Using STOPPFrail Drug Criteria <b>Sophie E Mayer, Virginia Pate, Laura C Hanson, Michele Jonsson Funk, Keturah R Faurot, Til Stürmer and Jennifer L Lund</b>
1:15 PM	Session OR30 Pediatric Potpourri – South Hall 2B	Cost Effectiveness of Early Treatment in Pediatric Patients With Hepatitis C Virus Infection <b>Joehl T Nguyen, A. Sidney Barritt, IV and Ravi Jhaveri</b>

#### ANNUAL ISPE MEETING AND AWARDS CEREMONY. CONGRESS HALL, 2:35 PM - 3:30 PM

**Andrew McAfee Award:** *Tiansheng Wang* (senior author); **Third best student abstract:** *Suzanne Landi*  
**Ronald Mann Best Paper Award from PDS:** *Honorable Mention: Til Stürmer* (co-author); **FISPE:** *Michele Jonsson Funk*

**SATURDAY, AUGUST 25. POSTER SESSION B, CONGRESS FOYER 2 & 3, 8AM-6PM**

Session	Poster
PO02-06 Study design and bias	Presentation 486 / 7 Application of the Prevalent New-User Design Among Commercially-Insured US Patients (Marketscan 2006-2015) <b>Arti Virkud, Jeff Yang, Virginia Pate and Til Stürmer</b>
PO02-06 Study design and bias	Presentation 493 / 14 Estimating Influenza Vaccine Effectiveness Using An Active Comparator Reduces Bias Due to Confounding by Frailty <b>Anne M Butler, J Bradley Layton, Whitney S Krueger, Abhijit V Kshirsagar and Leah J McGrath</b>
PO02-13 Geriatric Pharmacoepi	Presentation 634 / 155 Potential Omissions of Angiotensin Inhibition Treatment Among Older US Adults After An Acute Myocardial Infarction <b>Marcela Jiron, Virginia Pate, Laura C Hanson, Jennifer Lund, Michele Jonsson Funk and Til Stürmer</b>
PO02-13 Geriatric Pharmacoepi	Presentation 635 / 156 Potential Omissions of Oral Anticoagulant Among Older US Adults With Newly Diagnosed Atrial Fibrillation <b>Marcela Jiron, Virginia Pate, Laura C Hanson, Jennifer Lund, Michele Jonsson Funk and Til Stürmer</b>
PO02-13 Geriatric Pharmacoepi	Presentation 642 / 163 Potentially Inappropriate Medication Use and Emergency Department Visits in Older Women Diagnosed With Breast Cancer Initiating Chemotherapy <b>Danielle S Chun, Sharon Peacock-Hinton and Jennifer L Lund</b>
PO02-13 Geriatric Pharmacoepi	Presentation 644 / 165 Polypharmacy and Frailty in a Longitudinal Community-Based Cohort Study <b>Shahar Shmuel, Jennifer L Lund, Carolina Alvarez, Christine D Hsu, Priya Palta, Anna M Kucharska-Newton, Amanda E Nelson, and Yvonne M Golightly</b>
PO02-13 Geriatric Pharmacoepi	Presentation 646 / 167 Improving Population-Level PIM Exposure Metrics Using Medicare Claims Data <b>Jennifer L Lund, Virginia Pate, Marcela Jiron, Laura C Hanson, Shahar Shmuel, Michael A Webster-Clark, Joel F Farley and Til Stürmer</b>
PO02-14 Health Economics/Outcomes research	Presentation 679 / 200 Coverage and Out-Of-Pocket Spending on Brand versus Generic/Biosimilar Specialty Drugs in Medicare Part D <b>Stacie B Dusetzina, Shelley A Jazowski, Ashley L Cole and Joehl Nguyen</b>

**SPOTLIGHT POSTER PRESENTATIONS, CONGRESS FOYER 3A, 11:45 PM – 12:45 PM**

PO02-03 DUR/HSR	Presentation 460 / U Recent Trend of Antidiabetic Medications Use and Hypoglycemia Among T2DM in the U.S. Commercially Insured Population <b>Gang Fang and Izabela E Annis</b>
PO02-03 DUR/HSR	Presentation 462 / W Post-Surgical Opioid Prescriptions and Risk of Long-Term Use in the US <b>Jessica C Young, Nabarun Dasgupta, Brooke A Chidgey and Michele Jonsson Funk</b>

**UNC ALUMNI RECEPTION**

Please join us for a UNC Alumni Reception on Saturday, August 25 from 6:30 – 7:30 PM (prior to the ICPE Social Evening) at the Vyšehradský restaurant Kandelábr, QUBIX Office Building, Štětkova 1638/18, 140 00 Praha 4, Czechia. Shuttle bus for the ICPE Social at Municipal House begins at 7:00 pm, Entrance 10 / Congress Centre.

**SUNDAY, AUGUST 26. ORAL PRESENTATIONS & SYMPOSIA**

Time	Session & Room	Presentation
8:30 AM	OR14 Drugs in Pregnancy - Metformin, vareniclin, OCs, Methods – <b>South Hall 2A</b>	Presentation 768 Metformin versus Insulin for Initial Treatment of Gestational Diabetes: Maternal and Neonatal Outcomes <b>Suzanne Landi, Sarah Radke, Kim Boggess, Stephanie M Engel, Til Stürmer, Anne S Howe and Michele Jonsson Funk</b>
8:45 AM	OR14 Drugs in Pregnancy - Metformin, vareniclin, OCs, Methods – <b>South Hall 2A</b>	Presentation 769 Child Growth and Developmental Outcomes Following In-Utero Exposure to Metformin versus Insulin for Treatment of Gestational Diabetes <b>Suzanne N Landi, Sarah Radke, Stephanie M Engel, Til Stürmer, Kim Boggess, Anne S Howe and Michele Jonsson Funk</b> <i>3<sup>rd</sup> Best Student Abstract</i>
10:30 AM	WK03-04 It Takes a Village Part II: Workshop – <b>South Hall 1 A&amp;B</b>	Presentation 788 It Takes a Village Part II: Workshop to Reconsider Core Competencies for New Generations in the Global and Rapidly Changing Community of Pharmacoepidemiology <i>Soko Setoguchi, Paul Stang, Susana Perez-Gutthann, Frank May, Olaf Klungel, Brian Strom, Leyla Sahin, Pia Caduff, Wei Zhou, Jessica C. Young, Chien Chou Su, Laura Hester, Yanmin Zhu, Carolyn Cesta, Mohammed Zabiuddin Ahad, Daniel Horton, Sonia Hernandez-Diaz</i>

1:45 PM	OR36 Safety in Numbers – South Hall 3A	Presentation 822 Association Between Fluoroquinolone Use and Anterior Cruciate Ligament Injury in the United States <b>Mackenzie M Herzog, Jennifer L Lund, Virginia Pate, Jeffrey T Spang and Stephen W Marshall</b>
3:15 PM	Congress Hall	Hot Topics Session: New versus prevalent user designs in PE: time to get principled about when we can be pragmatic <b>Sonia Hernandez-Diaz, Jan Vandenbroucke, Til Stürmer, Jesper Hallas</b>

### SUNDAY, AUGUST 26. POSTER SESSION C, CONGRESS FOYER 2A, 8AM – 1:45 PM

Session	Poster
PO03-08 Drug Utilization - Other	Presentation 909 / 44 Patterns of Hormonal Contraceptive Use in the Self Cohort <b>Sarah R Hoffman, Jennifer S Smith, Donna D Baird and Quaker E Harmon</b>
PO03-10 Drug Utilization - Quality of use of medicines	Presentation 978 / 113 Slow Adoption of New Evidence Into Clinical Practice and Associated Factors: the Case of Duplicate Therapy With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers <b>Ryan P Hickson, James Terenyi, Ross J Simpson, Jr, Izabela E Annis, Keiko Bury and Gang Fang</b>
PO03-11 Pharmacovigilance - Alimentary tract&metabolism	Presentation 981 / 116 GLP-1RAs and Risk of Diabetic Retinopathy: Analysis of the FDA Adverse Event Reporting System Database <b>Wenchao Lu, Huilin Tang, Luwen Shi and Tiansheng Wang</b> <b>Andrew McAfee Award</b>
PO03-12 Pharmacovigilance - Cardiovascular	Presentation 1026 / 161 Short Term Hdl Cholesterol (HDL-C) Decrease and Incidence of Cardiovascular (CV) Events <b>Gema Requena, Julia DiBello, Liyuan Ma, Til Stürmer and Bradley Layton</b>
PO03-18 Quality of life	Presentation 1074 / 209 Cost-Utility of Screening for Renal Dysfunction to Detect the Onset and Progression of Chronic Kidney Disease Among Elderly Patients Treated With Proton-Pump Inhibitors <b>Jeff Y Yang, Emily H Chang, Stephanie B Wheeler and Evan S Dellon</b>
PO03-22 Benefit-Risk Assessment, Communication, and Evaluation	Presentation 1129 / 264 Limitations in Reporting "Benefit-Risk" Across Therapeutic Areas in Medical Device Literature <b>Whitney S Krueger, Jessica C Young, Kelly Hollis, A Brett Hauber, Alicia Gilsenan and Mary E Ritchey</b>

### SPOTLIGHT POSTER PRESENTATIONS, CONGRESS FOYER 3A, 12:15 PM – 1:15 PM

PO03-02 Molecular Epi, Biomarkers& Pharmacogenetics	Presentation 837 / K Pharmacogenomics of HIV in East Africa: Characterizing Drug Resistant Mutations (DRMS) in the Cross-Border Integrated Health Study, 2016 <b>Arti V Virkud, Jessie Edwards, Grace Mulholland, Milissa Markiewicz and Peter Arimi</b>
PO03-03 Oncology	Presentation 846 / T Association of Exogenous Hormone Use with Breast Cancer Subtype Defined by Oncotype DX Recurrence Score <b>Halei Benefield, Katherine Reeder-Hayes, Stephanie Wheeler, Lisa Carey, Andrew Olshan and Melissa Troester</b>

### Featuring collaborations with the following institutions:

Aarhus University, Denmark	IBM Watson Health	National Institute of Environmental Health Sciences	Universidad de Chile
Brigham and Women's Hospital	Indiana University	North Carolina State University	University of Auckland
Duke University	IQVIA	NoviSci	University of Manchester
Evidera	Leiden University	Peking University, China	University of Minnesota
GlaxoSmithKline	London School of Hygiene and Tropical Medicine	Rutgers Biomedical and Health Sciences	University of Southern Denmark, Odense
Harvard T.H. Chan School of Public Health	Merck	RTI Health Solutions	Vanderbilt University
Healthcore	National Cancer Institute (NCI)		Washington University

Funding for student travel to ICPE supported, in part, by the Center for Pharmacoepidemiology, Dept of Epidemiology at UNC Chapel Hill. Current members include **GlaxoSmithKline, Merck, Shire, and UCB Biosciences.**



### Connect with us! **UNC Pharmacoepidemiology**

Facebook: [facebook.com/UncPharmacoepidemiology](https://www.facebook.com/UncPharmacoepidemiology)

Twitter: @UNC\_RxEpi

LinkedIn: [UNC Pharmacoepidemiology](https://www.linkedin.com/company/unc-pharmacoepidemiology)

